New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - carbamazepine 20 mg/ml;   - syrup - 100 mg/5ml - active: carbamazepine 20 mg/ml   excipient: caramel hyetellose macrogol stearate 400 methyl hydroxybenzoate powdered cellulose propyl hydroxybenzoate propylene glycol purified water saccharin sodium sorbic acid sorbitol - epilepsy - complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalization. - generalized tonic-clonic seizures. mixed forms of seizures. tegretol® is suitable for both monotherapy and combination therapy. tegretol is usually not effective in absences (petit mal) and myoclonic seizures

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - carbamazepine 200mg;  ;   - tablet - 200 mg - active: carbamazepine 200mg     excipient: carmellose sodium colloidal silicon dioxide magnesium stearate microcrystalline cellulose - · epilepsy - complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalization. - generalized tonic-clonic seizures. mixed forms of seizures. tegretol® is suitable for both monotherapy and combination therapy. tegretol is usually not effective in absences (petit mal) and myoclonic seizures

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - carbamazepine 400mg;   - tablet - 400 mg - active: carbamazepine 400mg   excipient: carmellose sodium colloidal silicon dioxide magnesium stearate microcrystalline cellulose - · epilepsy - complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalization. - generalized tonic-clonic seizures. mixed forms of seizures. tegretol® is suitable for both monotherapy and combination therapy. tegretol is usually not effective in absences (petit mal) and myoclonic seizures

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - carbamazepine 200mg;  ;   - modified release tablet - 200 mg - active: carbamazepine 200mg     excipient: carmellose sodium colloidal silicon dioxide ethylcellulose hypromellose yellow, red, white suspension iron oxide red iron oxide yellow magnesium stearate methacrylic acid copolymer microcrystalline cellulose polyethylene glycol hydrogenated castor oil purified talc   purified water titanium dioxide - epilepsy - complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalization. - generalized tonic-clonic seizures. mixed forms of seizures. tegretol® is suitable for both monotherapy and combination therapy. tegretol is usually not effective in absences (petit mal) and myoclonic seizures

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - carbamazepine 400mg;   - modified release tablet - 400 mg - active: carbamazepine 400mg   excipient: carmellose sodium colloidal silicon dioxide ethylcellulose hypromellose yellow, red, white suspension iron oxide red iron oxide yellow magnesium stearate methacrylic acid copolymer microcrystalline cellulose polyethylene glycol hydrogenated castor oil purified talc   purified water titanium dioxide - epilepsy - complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalization. - generalized tonic-clonic seizures. mixed forms of seizures. tegretol® is suitable for both monotherapy and combination therapy. tegretol is usually not effective in absences (petit mal) and myoclonic seizures

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - carbamazepine, quantity: 200 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; carmellose sodium - 1. epilepsy: complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalisation; generalised tonic-clonic seizures; mixed seizure patterns incorporating the above. tegretol is suitable for monotherapy and combination therapy. tegretol is usually not effective in absence seizures, atonic seizures and myoclonic seizures and should not be used for status epilepticus (see "precautions"). 2. trigeminal neuralgia: for relief of pain in idiopathic trigeminal neuralgia and trigeminal neuralgia due to multiple sclerosis; and in idiopathic glossopharyngeal neuralgia. (tegretol is not a simple analgesic and is not intended for trivial facial pain or headache). 3. mania and bipolar affective disorders: treatment of mania and maintenance treatment of bipolar affective disorders to prevent or attenuate recurrence.

Israel - English - Ministry of Health

novartis israel ltd - carbamazepine - tablets - carbamazepine 200 mg - carbamazepine - carbamazepine - epilepsy, trigeminal neuralgia, diabetes insipidus, mania, prophylactic in manic depressive illness.

Israel - English - Ministry of Health

novartis israel ltd - carbamazepine - syrup - carbamazepine 100 mg / 5 ml - carbamazepine - carbamazepine - epilepsy, trigeminal neuralgia, diabetes insipidus, mania, prophylactic in manic-depressive illness.

Israel - English - Ministry of Health

novartis israel ltd - carbamazepine - tablets slow release - carbamazepine 400 mg - carbamazepine - carbamazepine - epilepsy, trigeminal neuralgia, diabetes insipidus, mania, prophylactic in mania depressive illness.

Israel - English - Ministry of Health

novartis israel ltd - carbamazepine - tablets slow release - carbamazepine 200 mg - carbamazepine - carbamazepine - epilepsy, trigeminal neuralgia, diabetes insipidus, mania, prophylactic in manic-depressive illness